Therapeutics of Platelet Glycoprotein IIb/IIIa Receptor AntagonismGowda, Ramesh M1; Khan, Ijaz A2*; Vasavada, Balendu C1; Sacchi, Terrence J1American Journal of Therapeutics: July/August 2004 - Volume 11 - Issue 4 - p 302-307 doi: 10.1097/01.mjt.0000071284.87458.a4 Therapeutic Reviews Buy Abstract Author InformationAuthors Article MetricsMetrics The integrin glycoprotein IIb/IIIa receptor is the final common pathway to platelet aggregation. Administration of glycoprotein IIb/IIIa receptor antagonists reduces acute ischemic complications following plaque fissuring or rupture. Research on this subject was initially limited to patients undergoing percutaneous coronary intervention. Further studies evaluating the role of glycoprotein IIb/IIIa receptor antagonists in patients with non-ST segment elevation acute coronary syndrome have shown benefit of these drugs in reducing adverse cardiac events and death. Intravenous glycoprotein IIb/IIIa receptor inhibitors (abciximab, tirofiban, and eptifibatide) given in combination with traditional regimens are superior to placebo in management of non-ST elevation acute myocardial infarction. Oral glycoprotein IIb/IIIa receptor inhibitors (orbofiban, sibrafiban, and xemilofiban) are not effective in reducing ischemic events when used on a long-term basis after acute coronary syndrome. Pharmacokinetics, efficacy, and safety of glycoprotein IIb/IIIa receptor antagonists are elaborated. 1Division of Cardiology, Long Island College Hospital, Brooklyn, New York; and 2Creighton University School of Medicine, Omaha, Nebraska. No financial support was received for this paper. *Address for correspondence: Creighton University Cardiac Center, 3006 Webster Street, Omaha, NE 68131.E-mail: email@example.com © 2004 Lippincott Williams & Wilkins, Inc.